Invivyd (IVVD) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

IVVD · Stock Price

USD 1.43+0.78 (+121.36%)

Market Cap: $418.7M

Historical price data

Market Cap: $418.7MPipeline: 7 drugs (4 Phase 3)Founded: 2020HQ: New Haven, United States

Sector Ranking#135 in Biologics / Biosimilars #25 in AI / Machine Learning

Overview

Invivyd's mission is to deliver protection from serious viral infectious diseases by developing rapidly-adaptable monoclonal antibody therapies. The company has achieved key milestones, including positive Phase 3 results for its COVID-19 candidate and an Emergency Use Authorization from the U.S. FDA. Its strategy leverages a proprietary, integrated technology platform to monitor viral evolution and engineer potent, variant-resistant antibodies, positioning it as a critical player in pandemic preparedness and the management of endemic viral diseases.

Infectious DiseaseRespiratory Diseases

Technology Platform

An integrated platform combining predictive viral surveillance and modeling with advanced antibody engineering to rapidly develop and adapt monoclonal antibody therapies that stay ahead of viral evolution.

Pipeline

7

7 drugs in pipeline4 in Phase 3

Drug	Indication	Stage
VYD2311-SD + VYD2311-MD + Placebo	COVID-19	Phase 3
VYD222 (pemivibart) + Normal saline	COVID-19	Phase 3
ADG20 + Normal saline	COVID-19	Phase 2/3
ADG20 + Placebo	COVID-19	Phase 2/3
VYD222	COVID-19	Phase 1

Opportunities

The primary opportunity lies in addressing the persistent, unmet need for effective COVID-19 prophylaxis in millions of immunocompromised individuals globally.

Expansion into the massive seasonal influenza market with a long-acting prophylactic antibody represents a significant future growth vector, leveraging the same rapid-adaptation platform.

Risk Factors

Key risks include the potential for viral evolution to outpace the company's development cycle, rendering its antibodies obsolete.

As a pre-revenue company, it faces financial sustainability risks and intense competition from large pharma vaccines, antivirals, and other antibody developers.

Competitive Landscape

Invivyd competes with large vaccine developers (Pfizer, Moderna) by complementing their products, and with other biotech mAb developers by emphasizing a platform built for rapid re-engineering against variants. Its success depends on demonstrating superior speed and variant-resilience.